Pulmonary Pharmacology & Therapeutics

Papers
(The median citation count of Pulmonary Pharmacology & Therapeutics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension73
Editorial Board53
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia43
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis39
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis37
Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis37
Editorial Board35
Editorial Board30
Effect of centrally and peripherally acting GABAB agonism on the healthy human cough reflex25
Editorial Board25
Risk factors associated with increased discontinuation rate of trimethoprim–sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study22
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study21
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study20
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis19
Mechanistic insights into the amelioration effects of lipopolysaccharide-induced acute lung injury by baicalein: An integrated systems pharmacology study and experimental validation19
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis18
Editorial Board18
Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels18
Enlightening clinical and therapeutic heterogeneity in thoracic actinomycosis: A review in bronchiectasis and non-bronchiectasis patients17
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers17
Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry16
Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways16
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)16
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers15
FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer13
Ensifentrine approval: A milestone in the treatment of COPD13
Corrigendum to “Presence and function of β-adrenergic receptors in primary equine bronchial epithelia cells” [Pulm Pharmacol Ther. (2020 Apr) 61 101897] DOI: 10.1016/j.pupt.2020.10189712
HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB311
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies11
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation11
Development of an inhaled anti-TSLP therapy for asthma10
Chrysin prevents lipopolysaccharide-induced acute lung injury in mice by suppressing the IRE1α/TXNIP/NLRP3 pathway10
Applicability of mouse models for induction of severe acute lung injury10
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study9
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis9
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia9
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway9
IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway9
The roles of immune system and autoimmunity in pulmonary arterial hypertension: A review9
Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma8
Dihydroquercetin (DHQ) ameliorates LPS-induced acute lung injury by regulating macrophage M2 polarization through IRF4/miR-132-3p/FBXW7 axis8
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics8
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome8
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma7
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study7
Editorial Board7
Editorial Board7
Editorial Board7
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 7
Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-197
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients6
Editorial Board6
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d6
Editorial Board6
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers6
NEK-mediated barrier regulation5
IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury5
Allopurinol treatment reduced vascular remodeling and improved vascular functions in monocrotaline-induced pulmonary hypertensive rats5
Impacts of deficiency in vitamin D derivatives on disease severity in adult bronchial asthma patients5
The involvement of Sting in exacerbating acute lung injury in sepsis via the PARP-1/NLRP3 signaling pathway5
Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects5
Prevalence and clinical significance of pre- and post-bronchodilator airflow obstruction in COPD patients5
Leukotriene inhibition and the risk of lung cancer among U.S. veterans with asthma5
A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells5
Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study5
WITHDRAWN: Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer5
Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb165
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function5
Which LABA/LAMA should be chosen in COPD patients in real life?5
Effect of functional principle, delivery technique, and connection used on aerosol delivery from different nebulizers: An in-vitro study4
Real world outcomes of CFTR modulator therapy in Australian adults and children4
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a4
Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension4
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease4
Inhaled vs. Intravenous Vasodilators in Perioperative Pulmonary Hypertension during Chest Surgery Using Cardiopulmonary Bypass: A Systematic Review and Meta-analysis4
Pulmonary drug delivery for acute respiratory distress syndrome4
The inflammatory regulation of TRPA1 expression in human A549 lung epithelial cells4
May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?4
Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol4
Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population4
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens4
Commercial α1-antitrypsin preparations markedly differ in their potential to inhibit the ATP-induced release of monocytic interleukin-1β4
Editorial Board4
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality4
Editorial Board4
Corrigendum to “Bleomycin induced lung fibrosis increases work of breathing in the mouse” [Pulm. Pharmacol.Therapeut. 25 (2012) 281-285]3
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study3
Statins’ still controversial role in pulmonary fibrosis: What does the evidence show?3
Editorial Board3
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets3
Chest CT assess the impact of omalizumab treatment on airway remodeling in refractory asthma3
Medication use in people with cystic fibrosis before and after modulator therapy3
Differential effects of dexamethasone and roflumilast on asthma in mice with or without short cigarette smoke exposure3
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway3
Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer3
Editorial Board3
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea3
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential3
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats3
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α3
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression3
Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions3
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling3
Corrigendum to “Myricetin inhibits TNF-α-induced inflammation in A549 cells via the SIRT1/NF-κB pathway” [Pulm. Pharmacol. Therapeut. 65 (2020) 102000]3
“The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension”3
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians3
Corrigendum to “Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat” [Pulm. Pharmacol. Therapeut. (88), March 2025, 102342]3
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients3
0.15360593795776